Clinical Trial Detail

NCT ID NCT03064854
Title PDR001 in Combination With Platinum-doublet Chemotherapy in PD-L1 Unselected, Metastatic NSCLC Patients (ElevatION:NSCLC-101 Trial)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Novartis Pharmaceuticals
Indications

non-small cell lung carcinoma

Therapies

Carboplatin + Paclitaxel + PDR001

Cisplatin + Pemetrexed + PDR001

Cisplatin + Gemcitabine + PDR001

Pemetrexed + PDR001 + Cisplatin + Carboplatin

Age Groups: adult senior

Additional content available in CKB BOOST